What You Should Know:
- Brainlab, a digital medical technology company based in
Munich, Germany has acquired Level Ex, a digital health startup creating
medical video games designed to advance the clinical skills of physicians and
surgeons.
- The acquisition will accelerate product development, allow Level Ex to enter new clinical areas faster, and expand its footprint in global markets, benefitting more medical professionals across a wider-range of specialties and cases.
- Level Ex
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
MD Anderson, Philips Partner on Personalized Oncology Treatments, Clinical Trial Matching
What You Should Know:
- Philips and MD Anderson collaborate to facilitate
personalized oncology treatments and clinical trial matching based on genomic
markers.
- Philips connects oncologists and pathologists around
the world to MD Anderson’s Precision Oncology Decision Support (PODS) system of
actionable clinical information
Philips and The University of Texas MD Anderson Cancer
Center today announced a collaboration to provide oncologists with
evidence-based therapy and clinical
Read More
Backed by Northwell, Conversa Health Raises $12M for AI-Powered Chatbots
What You Should Know:
- Conversa Health raises $12 million in Series B funding
round to expand its AI-powered chatbots enabling health systems, payers and pharmaceutical
companies to engage patients and collect patient-generated health data and
patient-reported outcomes.
- Conversa plans to use the funding to scale its virtual
care and communication platform—97 percent of patients who have used its chatbots
say they can better manage their care with Conversa.
- Murray Brozinsky
Read More
Consumer Genetic Tests Accelerate Precision Medicine for Some Providers
Joel Diamond, MD, FAAFP, Chief Medical Officer at 2bPrecise
Direct-to-consumer (DTC) genetic tests have been on the scene for some time now. The Federal Drug Administration (FDA) approved the first DTC test on three specific BRCA1/BRCA2 breast cancer gene mutations more than two years ago. Six months after that, the agency similarly green-lighted a DTC pharmacogenomic (PGx) test to examine 33 variants for eight different genes that indicate how effectively patients metabolize specific
Read More
Oncologists Believe Social Determinants of Health Impacts Outcomes for Cancer Patients
What You Should Know:
- Oncologists state social determinants of health (SDOH) significantly impact outcomes for cancer patients, according to new research from Cardinal Health Specialty Solutions.
- The findings illustrate certain disconnects between physician perceptions and the increasing body of evidence on the significance of SDOH.
- Appropriately, 91 percent of respondents agreed or strongly agreed that SDOH directly impact cancer treatment outcomes.
More than 90% of
Read More
Syapse Lands $30M to Accelerate Real-World Evidence in Oncology
What You Should Know:
- Syapse raises $30M in new equity funding to enable healthcare providers to deliver the best care to every cancer patient through precision medicine.
- Syapse partners with health systems, life sciences companies, and regulators to deliver clinical, programmatic, and research insights from the world’s largest network of health systems focused on precision medicine.
Syapse, a San
Francisco, CA-based provider of precision oncology
solutions announced $30
Read More
Value-Based Care’s Story Will Turn in the 2020s
Daniel Kus, VP of Pharmacy Services at Henry Ford Health System Troy Polan, acting CEO of ExceleraRx Corp
Value-based care initiatives matured in recent years thanks to exciting new technology and influential policy changes. But the coming decade will see transformative changes that will eventually lead to a uniform realization of value-based care across the entire healthcare continuum.
Specialty pharmacy represents one area of healthcare that is wholeheartedly welcoming a discussion
Read More
Biofourmis Acquires Digital Therapeutics Oncology Startup Gaido Health
What You Should Know:
- Boston-based digital therapeutics startup Biofourmis acquires LA-based Gaido Health from Takeda Pharmaceuticals, in a strategic deal that expands Biofourmis’ portfolio in the oncology space.
- Gaido Health—a digital therapeutics company focused on the oncology market—was part of Takeda Digital Ventures, Takeda’s corporate technology investment and incubation arm.
- With Gaido Health’s and Biofourmis’ dual focus on remote monitoring with wearables
Read More
Analysis: Applying AI in the Fight Against The Coronavirus
Dr. Ulrik Kristensen, Senior Market Analyst at Signify Research
Drug discovery is a notoriously long, complex and expensive process requiring the concerted efforts of the world’s brightest minds. The complexity in understanding human physiology and molecular mechanisms is increasing with every new research paper published and for every new compound tested. As the world is facing a new challenge in trying to both adapt to and defend itself against the coronavirus, artificial intelligence is
Read More
TeraRecon Acquired by SymphonyAI: What is the Impact for Medical Imaging Market?
On the 4th March 2020, TeraRecon announced it had signed an agreement to be acquired by the SymphonyAI Group. Here are the facts of the deal, followed by our take on the potential impact on the medical imaging market:
- The terms of the deal were not disclosed and TeraRecon will continue to operate business as usual. However, it will benefit from greater financial backing and the synergistic technologies from other companies in the Group’s portfolio.
- TeraRecon is an Advanced
Read More
